Cargando…
Early drotrecogin alpha (activated) administration in severe sepsis is associated with lower mortality: a retrospective analysis of the Canadian ENHANCE cohort
INTRODUCTION: Early multimodal treatment of severe sepsis, including the use of drotrecogin alfa (activated) (DrotAA) when indicated, is considered essential for optimum outcome. However, predicting which infected patients will progress to severe sepsis and the need for aggressive intervention conti...
Autores principales: | Hodder, Richard V, Hall, Richard, Russell, James A, Fisher, Harold N, Lee, Bobbie |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2717441/ https://www.ncbi.nlm.nih.gov/pubmed/19457240 http://dx.doi.org/10.1186/cc7893 |
Ejemplares similares
-
Canadian ENHANCE data support the efficacy and safety of drotrecogin alfa (activated) despite higher disease severity than the global ENHANCE population
por: Hall, R, et al.
Publicado: (2005) -
Introduction: severe sepsis and drotrecogin alfa (activated)
por: Artigas, Antonio, et al.
Publicado: (2007) -
Clinical trials in severe sepsis with drotrecogin alfa (activated)
por: Laterre, Pierre-François
Publicado: (2007) -
Timing of drotrecogin alfa (activated) treatment in severe sepsis
por: Choi, Goda, et al.
Publicado: (2006) -
Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?
por: Sadique, M Zia, et al.
Publicado: (2011)